Loading patent…
AssigneeMayo Foundation for Medical Education and Research
InventorsJohn A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
Estimating the term…
This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.
(canceled)
A method for reducing the number of cancer cells within a mammal in need thereof, wherein the method comprises administering, to the mammal, an inhibitor of an SCD1 polypeptide under conditions wherein the number of viable cancer cells present within the mammal is reduced, wherein the cancer cells are selected from the group consisting of thyroid cancer cells, melanoma cells, ovarian cancer cells, pancreatic cancer cells, renal cancer cells, and bladder cancer cells.
A method for reducing the number of cancer cells within a mammal, wherein the method comprises administering, to the mammal, a composition under conditions wherein the number of cancer cells present within the mammal is reduced, wherein the composition comprises the ability to reduce SCD1 mRNA expression or SCD1 polypeptide expression, wherein the cancer cells are selected from the group consisting of thyroid cancer cells, melanoma cells, ovarian cancer cells, pancreatic cancer cells, renal cancer cells, and bladder cancer cells.
Dependencies are inferred from the claim text.